DNA methylation profiles delineate etiologic heterogeneity and clinically important subgroups of bladder cancer
- PMID: 20802236
- PMCID: PMC2966555
- DOI: 10.1093/carcin/bgq178
DNA methylation profiles delineate etiologic heterogeneity and clinically important subgroups of bladder cancer
Abstract
DNA methylation profiles can be used to define molecular cancer subtypes that may better inform disease etiology and clinical decision-making. This investigation aimed to create DNA methylation profiles of bladder cancer based on CpG methylation from almost 800 cancer-related genes and to then examine the relationship of those profiles with exposures related to risk and clinical characteristics. DNA, derived from formalin-fixed paraffin-embedded tumor samples obtained from incident cases involved in a population-based case-control study of bladder cancer in New Hampshire, was used for methylation profiling on the Illumina GoldenGate Methylation Bead Array. Unsupervised clustering of those loci with the greatest change in methylation between tumor and non-diseased tissue was performed to defined molecular subgroups of disease, and univariate tests of association followed by multinomial logistic regression was used to examine the association between these classes, bladder cancer risk factors and clinical phenotypes. Membership in the two most methylated classes was significantly associated with invasive disease (P < 0.001 for both class 3 and 4). Male gender (P = 0.04) and age >70 years (P = 0.05) was associated with membership in one of the most methylated classes. Finally, average water arsenic levels in the highest percentile predicted membership in an intermediately methylated class of tumors (P = 0.02 for both classes). Exposures and demographic associated with increased risk of bladder cancer specifically associate with particular subgroups of tumors defined by DNA methylation profiling and these subgroups may define more aggressive disease.
Figures

Similar articles
-
DNA methylation array analysis identifies profiles of blood-derived DNA methylation associated with bladder cancer.J Clin Oncol. 2011 Mar 20;29(9):1133-9. doi: 10.1200/JCO.2010.31.3577. Epub 2011 Feb 22. J Clin Oncol. 2011. PMID: 21343564 Free PMC article.
-
Genomic DNA hypomethylation as a biomarker for bladder cancer susceptibility in the Spanish Bladder Cancer Study: a case-control study.Lancet Oncol. 2008 Apr;9(4):359-66. doi: 10.1016/S1470-2045(08)70038-X. Epub 2008 Mar 12. Lancet Oncol. 2008. PMID: 18339581 Free PMC article.
-
A prospective study of smoking-related white blood cell DNA methylation markers and risk of bladder cancer.Eur J Epidemiol. 2024 Apr;39(4):393-407. doi: 10.1007/s10654-024-01110-y. Epub 2024 Mar 30. Eur J Epidemiol. 2024. PMID: 38554236 Free PMC article.
-
Carcinogen exposure and gene promoter hypermethylation in bladder cancer.Carcinogenesis. 2006 Jan;27(1):112-6. doi: 10.1093/carcin/bgi172. Epub 2005 Jun 29. Carcinogenesis. 2006. PMID: 15987713
-
Specifics of spinal neuropathology in the molecular age.Neurooncol Adv. 2024 Feb 13;6(Suppl 3):iii3-iii12. doi: 10.1093/noajnl/vdad127. eCollection 2024 Oct. Neurooncol Adv. 2024. PMID: 39430396 Free PMC article. Review.
Cited by
-
Hypermethylation in bladder cancer: biological pathways and translational applications.Tumour Biol. 2012 Apr;33(2):347-61. doi: 10.1007/s13277-011-0310-2. Epub 2012 Jan 25. Tumour Biol. 2012. PMID: 22274923
-
Breast tumor DNA methylation patterns associated with smoking in the Carolina Breast Cancer Study.Breast Cancer Res Treat. 2017 Jun;163(2):349-361. doi: 10.1007/s10549-017-4178-8. Epub 2017 Mar 8. Breast Cancer Res Treat. 2017. PMID: 28275920 Free PMC article.
-
Heterogeneity Analysis of Bladder Cancer Based on DNA Methylation Molecular Profiling.Front Oncol. 2022 Jun 7;12:915542. doi: 10.3389/fonc.2022.915542. eCollection 2022. Front Oncol. 2022. PMID: 35747826 Free PMC article.
-
Epigenetics and Inflammatory Markers: A Systematic Review of the Current Evidence.Int J Inflam. 2019 May 8;2019:6273680. doi: 10.1155/2019/6273680. eCollection 2019. Int J Inflam. 2019. PMID: 31205673 Free PMC article. Review.
-
Emerging critical role of molecular testing in diagnostic genitourinary pathology.Arch Pathol Lab Med. 2012 Apr;136(4):372-90. doi: 10.5858/arpa.2011-0471-RA. Arch Pathol Lab Med. 2012. PMID: 22458900 Free PMC article. Review.
References
-
- Schilsky RL. Personalized medicine in oncology: the future is now. Nat. Rev. Drug Discov. 2010;9:363–366. - PubMed
-
- Genomic Health, Inc. Oncotype Dx Breast Cancer Assay Website. Redwood City, CA: Genomic Health, Inc; 2010.
-
- Wikman H, et al. Gene expression and copy number profiling suggests the importance of allelic imbalance in 19p in asbestos-associated lung cancer. Oncogene. 2007;26:4730–4737. - PubMed
-
- American Cancer Society. Cancer Facts and Figures 2009. Atlanta, GA: American Cancer Society; 2009.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical